124 related articles for article (PubMed ID: 10161507)
21. First choice for radiation-induced nausea and vomiting--the efficacy and safety of granisetron.
Goldsmith B
Acta Oncol; 2004 Sep; 43 Suppl 15():19-22. PubMed ID: 15370626
[No Abstract] [Full Text] [Related]
22. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
[TBL] [Abstract][Full Text] [Related]
23. 5-HT3-receptor antagonists in the control of delayed-onset emesis.
Gridelli C
Anticancer Res; 2003; 23(3C):2773-82. PubMed ID: 12926112
[TBL] [Abstract][Full Text] [Related]
24. Progress in controlling emesis with cancer chemotherapy.
Gralla RJ; Clark RA
Support Care Cancer; 1993 Jul; 1(4):178-81. PubMed ID: 8193878
[TBL] [Abstract][Full Text] [Related]
25. Stratified administration of serotonin 5-HT3 receptor antagonists (setrons) for chemotherapy-induced emesis. Economic implications.
Sanchez LA; Holdsworth M; Bartel SB
Pharmacoeconomics; 2000 Dec; 18(6):533-56. PubMed ID: 11227393
[TBL] [Abstract][Full Text] [Related]
26. Optimising antiemetic therapy: what are the problems and how can they be overcome?
Aapro M
Curr Med Res Opin; 2005 Jun; 21(6):885-97. PubMed ID: 15969889
[TBL] [Abstract][Full Text] [Related]
27. Promoting the use of oral ondansetron in children receiving cancer chemotherapy.
Walker PC; Biglin KE; Constance TD; Bhambhani K; Sims-McCallum R
Am J Health Syst Pharm; 2001 Apr; 58(7):598-602. PubMed ID: 11296610
[No Abstract] [Full Text] [Related]
28. The use of oral granisetron versus intravenous ondansetron for antiemetic prophylaxis in patients undergoing laparoscopic surgery: the effect on emetic symptoms and quality of recovery.
White PF; Tang J; Hamza MA; Ogunnaike B; Lo M; Wender RH; Naruse R; Sloninsky A; Kariger R; Cunneen S; Khalili T
Anesth Analg; 2006 May; 102(5):1387-93. PubMed ID: 16632815
[TBL] [Abstract][Full Text] [Related]
29. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
30. 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?
Aapro M; Blower P
Cancer; 2005 Jul; 104(1):1-18. PubMed ID: 15929119
[TBL] [Abstract][Full Text] [Related]
31. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
Herrstedt J
Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151
[TBL] [Abstract][Full Text] [Related]
32. Granisetron: is there a dose-response effect on nausea and vomiting?
Minami M
Cancer Chemother Pharmacol; 2003 Aug; 52(2):89-98. PubMed ID: 12783208
[TBL] [Abstract][Full Text] [Related]
33. Freeze dried ondansetron: first observations with the fast dissolving oral antiemetic Zofran Zydis for the prophylaxis of the cisplatin-induced emesis in gynecological cancer patients.
Lehoczky O; Udvary J; Pulay T
Neoplasma; 2002; 49(2):126-8. PubMed ID: 12088106
[TBL] [Abstract][Full Text] [Related]
34. Clinical practice guidelines on antiemetics in oncology.
Aranda Aguilar E; Constenla Figueiras M; Cortes-Funes H; Diaz-Rubio García E; Gascon Vilaplana P; Guillém V; Martin-Algarra S
Expert Rev Anticancer Ther; 2005 Dec; 5(6):963-72. PubMed ID: 16336087
[TBL] [Abstract][Full Text] [Related]
35. '... setron': are 5-HT3 receptor antagonists different?
Aapro MS
Eur J Cancer; 1993; 29A(12):1655. PubMed ID: 8398287
[No Abstract] [Full Text] [Related]
36. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?
de Wit R; Aapro M; Blower PR
Cancer Chemother Pharmacol; 2005 Sep; 56(3):231-8. PubMed ID: 15838653
[TBL] [Abstract][Full Text] [Related]
37. Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy.
de Wit R; de Boer AC; vd Linden GH; Stoter G; Sparreboom A; Verweij J
Br J Cancer; 2001 Oct; 85(8):1099-101. PubMed ID: 11710819
[TBL] [Abstract][Full Text] [Related]
38. The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy.
Carmichael J; Harris AL
Cancer Chemother Pharmacol; 2004 Feb; 53(2):123-8. PubMed ID: 14634790
[TBL] [Abstract][Full Text] [Related]
39. Effect of granisetron on performance status during high-dose interferon therapy.
Drapkin R; Barolo JL; Blower PR
Oncology; 1999 Nov; 57(4):303-5. PubMed ID: 10575316
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy-induced nausea and vomiting: challenges and opportunities for improved patient outcomes.
Hawkins R; Grunberg S
Clin J Oncol Nurs; 2009 Feb; 13(1):54-64. PubMed ID: 19193549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
